Bal Pharma Ltd Share Price

AGM Date: 24 Sep 2021

AGM 24/09/2021 We would like to notify the exchange that the register of members and share transfer books of the Company shall remain closed from 18.09.2021 to 24.09.2021 (both days inclusive) to ascertain the entitlement of Dividend and for the 34th Annual General Meeting of the Company, scheduled to be held on 24.09.2021. (As Per BSE Announcement dated on 05.07.2021) We are submitting herewith the Annual Report of the Company for the financial year 2020-21 along with the Notice of the 34th Annual General Meeting of the Company, scheduled to be held on Friday , 24th September 2021 at 11.00 A.M through Video Conferencing ('VC') / Other Audio-Visual Means ('OAVM'). A copy of the abridged Annual Report along with the Notice convening the 34th Annual General Meeting of the Company is being sent to all the shareholders of the Company. The remote e-voting period shall commence on Tuesday ,21st September 2021 at 09:00 a.m. and shall end on Thursday ,23rd September 2021, at 05:00 p.m. The Register of Members and Share Transfer Books of the Company shall remain closed from 18th September 2021 to 24th September 2021(both days inclusive) to ascertain the entitlement of Dividend, if any and for 34th Annual General Meeting of the Company. (As Per BSE Announcement dated on 01.09.2021) Proceedings of 34rd Annual General Meeting (AGM) held on 24.9.2021. Ref : Scrip code 524824 for BSE and BALPHARMA for NSE. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we are submitting to the exchange the business transacted at the 34rd Annual General Meeting of the Company conducted through audio visual means on 24.09.2021. Please take this intimation on record. (As Per BSE Announcement Dated on 9/24/2021 12:37:23 PM) We are submitting to the exchange the results of the remote e-voting for 34th Annual General Meeting of the Company held on 24.09.2021 along with the copy of scrutinizers report. The aforesaid reports are also available on our website i.e www.balpharma.com and also on the website of NSDL i.e www.evoting.nsdl.com. (As Per BSE Announcement Dated on 9/27/2021 5:54:17 AM)

AGM Date: 19 Sep 2022

AGM 19/09/2022 Register of Members and Share Transfer books of the Company will remain closed from 15th September 2022 to 19th September 2022 ( both days inclusive) to ascertain the entitlement of dividend and for the 35th Annual General Meeting of the Company scheduled to be held on 19.09.2022, i.e on Monday. Sub : Notice of 35th Annual General Meeting and submission of Annual Report for Financial Year 2021-2022 Ref : Regulation 34 of SEBI (LODR) Regulations,2015. As already informed to the exchanges, 35th Annual General Meeting of the Company is scheduled to be held on 19th September 2022 at 11.30 A.M through audio visual means. Notice along with the details of the business to be transacted at the meeting and audited financial statements of the Company for the F.Y ended 30.03.2022 together with the reports of Directors and auditors there on is being dispatched to our shareholders through electronic form. A Copy of the unabridged annual report of the Company for the financial year ended 31.03.2022 is enclosed for submission to the exchanges. Annual report for F.Y 2021.22 is also available on our website i.e www.balpharma.com (As Per BSE Announcement Dated on 26.08.2022) Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the 35th Annual General Meeting of the Company conducted through audio visual means, on 19.09.2022. (As Per BSE Announcement Dated on 19.09.2022) We are submitting to the exchange the results of the remote e-voting for 35th Annual General Meeting of the Company held on 19.09.2022, along with the copy of scrutinizers report. The aforesaid reports are also available on our website i.e www.balpharma.com. (As Per BSE Announcement Dated on 21.09.2022)

AGM Date: 25 Sep 2023

AGM 25/09/2023 Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Un-audited standalone and consolidated financial results of the Company for the quarter ended 30.06.2023. A copy of the approved financial results together with the limited review report issued by the statutory auditors of the Company with unmodified opinion is enclosed with this intimation. 2. Decided to convene 36th Annual General Meeting of the Company on 25th September 2023 i.e on Monday at 10:30 A.M, through audio visual means. 3. Decided to close the Register of Members and Share transfer books of the Company from 19.09.2023 to 25.09.2023 (both days inclusive) to ascertain the entitlement of Dividend and for the 36th Annual General Meeting of the Company. The meeting commenced at 4.30 p.m. and concluded at 5:40 p.m on Friday, 11th August 2023. (As Per BSE Announcement Dated on 11.08.2023) We are submitting to the exchange the results of the remove e-voting for 36th Annual General Meeting of the Company held on 25.09.2023 with a copy of scrutinizers report. (As Per BSE Announcement Dated on 27/09/2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 We are submitting to the exchanges the out come of the 37th Annual General Meeting of the Company held on 25.09.2024. (As Per BSE Announcement dated on 25.09.2024) We are submitting the Scrutinizers report on the e-voting done at the 37th Annual General Meeting of the Company held on 25.09.2024. (As per BSE Announcement dated on 26/09/2024)

AGM Date: 25 Sep 2025

Board of Directors of the Company has met today and inter alia transacted the following business, 1. Approved the unaudited financial results ( standalone and consolidated ) for the quarter ended 30.06.2025. 2. Convened 38th Annual General meeting of the company on 25th September 2025 at 11.30 am through AV means. 3. Decided to close the register of members from 19.09.2025 to 25.09.2025 ( both days inclusive ) 4. Approved the ESOP -2025 plan, subject to the approval of shareholders. 5. e-Voting dates from 22.09.2025 to 24.09.2025, for the ensuing Annual General Meeting Outcome of the 38th Annual General Meeting of the Company. (As Per BSE Announcement Dated on: 25/09/2025)

EGM Date: 14 Dec 2022

EGM 14/12/2022 Extra Ordinary General Meeting of the Company is scheduled to be held on 14th December 2022 at 11.30 a.m, through audio visual means. Notice along with the details of the business to be transacted at the meeting is being dispatched to our shareholders through electronic form. A Copy of the unabridged Notice for the EGM is enclosed for submission to the exchanges. Copy of the EGM notice is also available on our website i.e www.balpharma.com. Board of Directors of the Company has met today and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed . 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company. 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022. (As Per BSE Announcement Dated on 14.11.2022) Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting to the exchange the business transacted at the Extra Ordinary General Meeting of the Company conducted through audio visual means, on 14.12.2022. Mr.Shailesh Siroya was elected as Chairman and he chaired the proceedings of the meeting with requisite quorum. Special Business: 1. To seek the consent of the members for filing an application under Section 230(1) of the Companies Act, 2013 with National Company Law Tribunal, Bengaluru Bench in connection with proposed merger of Wholly Owned Subsidiary Company i.e Golden Drugs Private Limited (Transferor Company) with Bal Pharma Limited (Transferee Company). (As per BSE Announcement Dated on 14/12/2022) We are submitting to the exchanges the results of remote e-voting for Extra Ordinary General Meeting of the Company held on 14.11.2022, along with a copy of the Scrutinizers report. (As per BSE Announcement Dated on 16/12/2022)

EGM Date: 03 Oct 2023

We wish to inform that the Company has received order dated 24th August 2023 from Hon''ble National Company Law Tribunal , Bangalore bench ( NCLT) and received by us on 30.08.2023, directing the Company to convene meetings of equity shareholders, Secured and Unsecured creditors of the Company on Tuesday October 3 ,2023 , for the purpose of considering and if thought fit approving the proposed scheme of merger of Golden Drugs Pvt Ltd with Bal Pharma Ltd, its holding Company. The said order of NCLT is enclosed herewith and has also been made available on the Company''s website i.e www.balpharma.com.

EGM Date: 21 Dec 2023

Honorable Bangalore bench of National Company Law Tribunal has convened meetings of shareholders and creditors of Transferer Company i.e Golden Drugs Pvt Ltd and Transferee company i.e Bal Pharma Limited, on 21.12.2023 from 11.00 A.M through audio visual means to inter alia consider approval of scheme of arrangement /merger between transferer Company and Transferee Company. We are submitting to the exchanges newspaper publication of the Notice issued to the Shareholders and Creditors of Bal Pharma Ltd (Transferee Company) and its wholly owned subsidiary Golden Drugs Pvt Ltd (Transferer Company) for the NCLT convened meetings scheduled on 21.12.2023 and published in Financial Express (English) and Vijayavani (Kannada), on 20.11.2023. (As Per BSE Announcement Dated on 21.11.2023) Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations ,2015, we are submitting to the exchanges business transacted at the NCLT convened meetings of shareholders, secured and unsecured creditors of the Company, which was conducted through audio visual means on 21.12.2023 (As per BSE Announcement Dated on 21/12/2023) We are submitting to the exchange a copy of the scrutinizers report on the e-voting results of the NCLT convened shareholders meeting of the company held on 21.12.2023. Please take the same on record. (As per BSE Announcement Dated on 22/12/2023)